| Patient-related factors |
| Older age |
| Female gender |
| Race |
| Higher in African Americans |
| Lower in Asians/Pacific Islanders |
| Comorbidities |
| Infection, renal disease, pulmonary disease, obesity |
| Inherited prothrombotic mutations |
| Prior history of VTE |
| Cancer-related factors |
| Primary site of cancer |
| Brain, pancreas, kidney, stomach, |
| lung, gynecologic, lymphoma, myeloma |
| Advanced stage of cancer |
| Initial period after diagnosis of cancer |
| Treatment-related factors |
| Major surgery |
| Hospitalization |
| Cancer therapy |
| Chemotherapy |
| Hormonal therapy |
| Anti-angiogenic agents |
| Thalidomide, lenalidomide, bevacizumab |
| Erythropoiesis-stimulating agents |
| Transfusions |
| Central venous catheter |
| Candidate Biomarkers |
| Pre-chemotherapy platelet count ≥350,000/mm3
|
| Pre-chemotherapy leukocyte count>11,000/mm3
|
| Tissue factor (TF) |
| High grade of TF expression by tumor cells |
| Elevated TF plasma levels |
| Soluble P-selectin |
| D-dimer |
| C-reactive protein |
